Daniel L. Kastner

As of 2021 Kastner has said that he plans to leave his post of scientific director at NHGRI "in the next few months". He will continue to work with the 3,000 patients in his clinic, and "find yet more disease genes, understand how they work, and develop new treatments."

The chair of the Crafoord Prize committee, Olle Kämpe [sv], said in 2021:

He was awarded the 2021 Crafoord Prize in Polyarthritis, with the citation "for establishing the concept of autoinflammatory diseases".

In 2018 Kastner was named "Federal Employee of the Year" in the Samuel J. Heyman Service to America Medals ("the Sammies"). and in 2019 he won the Ross Prize for Molecular Medicine.

Kastner was elected to the National Academy of Sciences in 2010 and to the National Academy of Medicine in 2012.

His work has led to the recognition and treatment of a range of autoinflammatory disorders. In 1987 his was one of two teams which simultaneously discovered and published the genetic mutation which causes FMF, and since then he has worked on disorders including TRAPS and DADA2. In 2020 he was one of the authors of the paper which first described the VEXAS syndrome. As of 2021 he is working on Behçet's disease.

Kastner joined the National Institutes of Health in 1985 and as of 2020 is scientific director of the Division of Intramural Research of the National Human Genome Research Institute. His research there "has focused on using genetic and genomic strategies to understand inherited disorders of inflammation".

Kastner earned a BA in philosophy from Princeton University in 1973. and an MD and PhD from Baylor College of Medicine.

Daniel L. Kastner (born 1951) is an American physician and researcher specialising in the genetics of autoinflammatory disorders. He is scientific director of the National Human Genome Research Institute, where he is a National Institutes of Health Distinguished Investigator. He was awarded the 2021 Crafoord Prize for Polyarthritis for his pioneering work on autoinflammatory diseases.